ArticleEuropean journal of clinical pharmacology2023
Costs associated with adverse drug reactions in an older population admitted to hospital: a prospective cohort study.
Article in European journal of clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The association between age and medication-related hospital admission in adults: a systematic review and meta-analysis.International journal of clinical pharmacy · 2026Pooled it
- Hospital admissions due to adverse drug reactions and adverse drug events in older adults: a systematic review.Age and ageing · 2025Pooled it
- Trial
- How direct healthcare professional communications are operationalised by general practitioners and community pharmacists in Ireland: a national cross sectional study.International journal of clinical pharmacy · 2026Article
- Adverse Drug Reaction-Related Hospital Admissions and Adverse Drug Events and Their Association with Short- and Long-Term Health Outcomes in Older Adults.Geriatrics (Basel, Switzerland) · 2026Article
- The risk and cost of drug-drug interactions in an older population acutely admitted to hospital in Ireland.International journal of clinical pharmacy · 2025Article
- Identifying predictors of medication-related harm in older populations: a latent class analysis approach.Age and ageing · 2025Article
- Prospective Evaluation of Adverse Drug Reactions in Hospitalized Older Adults in Ethiopia.Journal of personalized medicine · 2025Article
- Adverse drug reactions and events in an Ageing PopulaTion risk Prediction (ADAPTiP) tool: the development and validation of a model for predicting adverse drug reactions and events in older patients.European geriatric medicine · 2025Article
- Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT-ECO study.British journal of clinical pharmacology · 2025Article
- Barriers to and facilitators of healthcare professionals in ADR reporting in a tertiary care hospital in India.BMC health services research · 2025Article
- A study on user willingness to participate in an adverse drug event information sharing system.BMC public health · 2024Article
- Recognizing and preventing unacknowledged prescribing errors associated with polypharmacy.Archives of public health = Archives belges de sante publique · 2024Article
- Economic cost-benefit analysis of person-centred medicines reviews by general practice pharmacists.International journal of clinical pharmacy · 2024Article
- A case-control study on the clinical characteristics of granisetron-related arrhythmias and the development of a predictive nomogram.International journal of clinical pharmacy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeThis study examines healthcare costs associated with adverse drug reactions (ADR) in an older population admitted acutely to an Irish tertiary hospital.
methodsProspective cohort study involving older persons admitted to hospital with and without an ADR. Data was collected at baseline, during hospitalisation and post-discharge. Participants provided information on healthcare resource use three months before admission (baseline) and three months after discharge (follow-up). For each healthcare resource, unit costs were derived and applied. The average cost (standard deviation (SD)) associated with the hospital admission for the ADR and non-ADR are presented. In addition, baseline and follow-up care costs were compared using difference-in-difference analysis and presented with 95% confidence intervals (CI). Costs by preventability and severity of ADR are also presented.
resultsA total of n = 230 participants were included (n = 93 ADR and n = 137 without ADR). The average cost associated with hospital admission for an ADR was €9538 (SD €10442) and €9828 (SD €11770) for non-ADR. The additional follow-up costs (difference-in-difference) associated with the ADR was estimated at €2047 (95% CI: -€889 to €4983). The mean incremental follow-up cost of definite preventable ADRs was estimated at €1648 (95% CI: -€4310 to €7605), possible preventable ADRs €2259 (95 CI: -€1194 to €5712) and unavoidable ADRs €1757 (95% CI: -€3377 to €6890). The mean incremental follow-up cost associated with moderate severe ADRs was estimated at €1922 (95% CI: -€1088 to €4932) and €3580 (95% CI: -€4898 to €12,058) for severe ADRs.
conclusionADRs leading to hospital admission are associated with modest incremental healthcare costs during and three months after admission. Severe and possibly preventable ADRs were associated with higher costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.